| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Obstetrics and Gynecology [G. I., O. O., U. P., K-D. S., G. E.] and Institute for Molecular Biology and Tumor Research [C. B., R. M.], Philipps University, D-35033 Marburg, Germany, and Department of Physiology and Biophysics [S. S. K., J. D. N.], University of Alabama at Birmingham, Birmingham, Alabama 35294
Recently we reported the presence of specific high affinity binding sites for luteinizing hormone-releasing hormone (LHRH) and its analogues (Kd = 1.5 or 1.7 nM) in the human epithelial ovarian cancer cell lines EFO-21 and EFO-27. The proliferation of these cell lines was inhibited by nM concentrations of a LHRH agonist. This study was performed to ascertain whether these ovarian cancer cell lines produce LHRH and whether the high affinity LHRH binding site found previously was identical to the pituitary LHRH receptor. Significant amounts of immunoreactive LHRH were found in the extracts of both the EFO-21 cell line (449 ± 56 fmol/106 cells) and the EFO-27 line (409 ± 76 fmol/106 cells). LHRH bioactivity of these extracts, assessed in terms of release of luteinizing hormone by rat pituitary cells, was comparable to that of authentic LHRH. EFO-21 and EFO-27 cells expressed the mRNAs for both human LHRH and human LHRH receptor as assessed by reverse transcriptase-PCR using oligonucleotide primers according to published sequences. In addition, in eight of eight biopsy samples of human epithelial ovarian cancers we detected mRNA for LHRH, six of these specimens expressed the mRNA representing the LHRH receptor. These data support the concept that human epithelial ovarian cancers might have a local system based on LHRH to regulate cell proliferation. It is still obscure at present whether LHRH produced locally has a stimulatory, inhibitory, or no impact on the proliferation of ovarian cancer cells. However, exogenous LHRH agonists seem to have clear antiproliferative activity, probably mediated through LHRH receptors. This finding might provide the base for novel approaches in the therapy of epithelial ovarian cancer.
1 This study was supported by the Deutsche Forschungsgemeinschaft (SFB 215, B10) and Graduiertenkolleg "Zell- und Tumorbiologie" (Marburg, Germany), P. E. Kempkes Foundation (Marburg, Germany), and Ferring Arzneimittel (Kiel, Germany), and by NIH Grant CA 60871.
2 To whom requests for reprints should be addressed, at Department of Obstetrics and Gynecology, Philipps-University, Pilgrimstein 3, D-35033 Marburg, Germany.
Received 6/28/94. Accepted 12/ 7/94.
This article has been cited by other articles:
![]() |
S. Fister, A. R. Gunthert, G. Emons, and C. Grundker Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1750 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W.T. Cheung, P. C.K. Leung, and A. S.T. Wong Gonadotropin-Releasing Hormone Promotes Ovarian Cancer Cell Invasiveness through c-Jun NH2-Terminal Kinase-Mediated Activation of Matrix Metalloproteinase (MMP)-2 and MMP-9. Cancer Res., November 15, 2006; 66(22): 10902 - 10910. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-Y. Kim, K.-C. Choi, N. Auersperg, and P. C K Leung Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr. Relat. Cancer, March 1, 2006; 13(1): 211 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Leuschner and W. Hansel Targeting Breast and Prostate Cancers Through Their Hormone Receptors Biol Reprod, November 1, 2005; 73(5): 860 - 865. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Eicke, A. R Gunthert, V. Viereck, D. Siebold, M. Behe, T. Becker, G. Emons, and C. Grundker GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs Eur. J. Endocrinol., October 1, 2005; 153(4): 605 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Tang, T. Yano, Y. Osuga, H. Matsumi, N. Yano, J. Xu, O. Wada, K. Koga, K. Kugu, O. Tsutsumi, et al. Cellular Mechanisms of Growth Inhibition of Human Epithelial Ovarian Cancer Cell Line by LH-Releasing Hormone Antagonist Cetrorelix J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3721 - 3727. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Kang, C.-J. Tai, P. S. Nathwani, K.-C. Choi, and P. C. K. Leung Stimulation of Mitogen-Activated Protein Kinase by Gonadotropin-Releasing Hormone in Human Granulosa-Luteal Cells Endocrinology, February 1, 2001; 142(2): 671 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Kang, C.-J. Tai, P. S. Nathwani, and P. C. K. Leung Differential Regulation of Two Forms of Gonadotropin-Releasing Hormone Messenger Ribonucleic Acid in Human Granulosa-Luteal Cells Endocrinology, January 1, 2001; 142(1): 182 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gründker, K. Schulz, A. R. Günthert, and G. Emons Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor {kappa}B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3815 - 3820. [Abstract] [Full Text] |
||||
![]() |
C.-T. Hsu, C.-Y. Ting, C.-J. Ting, T.-Y. Chen, C.-P. Lin, J. Whang-Peng, and J. Hwang Vaccination against Gonadotropin-releasing Hormone (GnRH) Using Toxin Receptor-binding Domain-conjugated GnRH Repeats Cancer Res., July 1, 2000; 60(14): 3701 - 3705. [Abstract] [Full Text] |
||||
![]() |
R. Grosse, A. Schmid, T. Schoneberg, A. Herrlich, P. Muhn, G. Schultz, and T. Gudermann Gonadotropin-releasing Hormone Receptor Initiates Multiple Signaling Pathways by Exclusively Coupling to Gq/11 Proteins J. Biol. Chem., March 24, 2000; 275(13): 9193 - 9200. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Limonta, R. M. Moretti, M. M. Marelli, D. Dondi, M. Parenti, and M. Motta The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway Endocrinology, November 1, 1999; 140(11): 5250 - 5256. [Abstract] [Full Text] |
||||
![]() |
I. Palyi, B. Vincze, S. Lovas, I. Mezo, J. Pato, A. Kalnay, G. Turi, D. Gaal, R. Mihalik, I. Peter, et al. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity PNAS, March 2, 1999; 96(5): 2361 - 2366. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Imai, A. Takagi, S. Horibe, H. Takagi, and T. Tamaya Evidence for Tight Coupling of Gonadotropin-Releasing Hormone Receptor to Stimulated Fas Ligand Expression in Reproductive Tract Tumors: Possible Mechanism for Hormonal Control of Apoptotic Cell Death J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 427 - 431. [Abstract] [Full Text] |
||||
![]() |
A. Nechushtan, S. Yarkoni, I. Marianovsky, and H. Lorberboum-Galski Adenocarcinoma Cells Are Targeted by the New GnRH-PE66 Chimeric Toxin through Specific Gonadotropin-releasing Hormone Binding Sites J. Biol. Chem., April 25, 1997; 272(17): 11597 - 11603. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |